A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals
Open Access
- 11 July 2017
- journal article
- Published by Case Western Reserve University in Pathogens and Immunity
- Vol. 2 (3) , 310-334
Abstract
Background: In HIV infection, lymphoid tissue is disrupted by fibrosis. Angiotensin converting enzyme inhibitors have anti-fibrotic properties. We completed a pilot study to assess whether the addition of lisinopril to antiretroviral therapy (ART) reverses fibrosis of gut tissue, and whether this leads to reduction of HIV RNA and DNA levels.Methods: Thirty HIV-infected individuals on ART were randomized to lisinopril at 20mg daily or matching placebo for 24 weeks. All participants underwent rectal biopsies prior to starting the study drug and at 22 weeks, and there were regular blood draws. The primary end point was the change in HIV RNA and DNA levels in rectal tissue. Secondary outcomes included the change in 1) HIV levels in blood; 2) Gag-specific T-cell responses; 3) levels of T-cell activation; and 4) collagen deposition.Results: The addition of lisinopril did not have a significant effect on the levels of HIV RNA or DNA in gut tissue or blood, Gag-specific responses, or levels of T-cell activation. Lisinopril also did not have a significant impact on lymphoid fibrosis in the rectum, as assessed by quantitative histology or heavy water labeling.Conclusions: Treatment with lisinopril for 24 weeks in HIV-infected adults did not have an effect on lymphoid fibrosis, immune activation, or gut tissue viral reservoirs. Further study is needed to see if other anti-fibrotic agents may be useful in reversing lymphoid fibrosis and reducing HIV levels.Clinical Trials Registration: NCT01535235Keywords
This publication has 43 references indexed in Scilit:
- Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV InfectionThe Journal of Infectious Diseases, 2011
- T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected WomenThe Journal of Infectious Diseases, 2011
- Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral TherapyThe Journal of Infectious Diseases, 2010
- IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the PeripheryJournal of Clinical Immunology, 2010
- Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV InfectionThe Journal of Infectious Diseases, 2009
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Incomplete Peripheral CD4+Cell Count Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral TreatmentClinical Infectious Diseases, 2009
- Collagen Deposition Limits Immune Reconstitution in the GutThe Journal of Infectious Diseases, 2008
- Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of TherapyThe Journal of Infectious Diseases, 2008
- Stromal Cell Networks Regulate Lymphocyte Entry, Migration, and Territoriality in Lymph NodesImmunity, 2006